Diagnostics specialists win the US device approval race
The speediest device developer is Roche, but a look at companies’ strategies shows the perils of relying on bought-in tech.
GTX Medical gains a new technology and loses a competitor
In buying a company previously thought of as a competitor GTX hopes to dominate the spinal cord injury space.
Admedus moves from one unlikely area to another
A product sale nets the Australian company some much-needed cash, but its plan for the future is highly questionable.
Menarini Silicon Biosystems banks on cells for its liquid biopsy
The group has the only approved cell-based cancer blood test in the world, but competing in an increasingly cutthroat market will be tough.
Storm-tossed Qiagen plots a course to higher growth
A shift to higher-growth systems and a tie-up with Illumina are sensible moves, but will take time to pay off.
TCT 2019 – Abbott's aortic valve disappoints
Portico hits noninferiority, but safety looks doubtful. Abbott might want to prioritise a different approach.
TCT 2019 – Orchestra data could lead to a duet
Data on the company’s pacemaker-neurostimulator combo are probably good enough to permit further development – but first the company wants to hook a partner.
Esmo 2019 – Foundation eyes liquid biopsy rule change
New data could change liquid biopsy guidelines and boost sales, though regulatory approval would not be a bad idea.
Medtronic bets on flexibility for its surgical robots
The long-awaited robotic surgery system is designed to open up the market.
Kickstarting ideas
Independent, data-driven daily news and analysis on pharma, biotech and medtech.